Edgestream Partners’s Editas Medicine EDIT Stock Holding History

Edgestream Partners’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-154,789	Closed	-$1.12M	–	760
2023 Q1	$1.12M	Sell	154,789 -144,112	-48%	-$1.28M	0.12%	277
2022 Q4	$2.65M	Buy	298,901 +84,098	+39%	+$923K	0.3%	95
2022 Q3	$2.63M	Buy	+214,803	New	+$3.35M	0.2%	167

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Edgestream Partners's EDIT Position: Q2 2023 in Review

Edgestream Partners sold out of Editas Medicine (EDIT) in Q2 2023, closing a stake of 154,789 shares — an estimated $1.12M sold.

Edgestream Partners first reported a position in EDIT in Q3 2022 and held it in 3 quarters. The position peaked at $2.65M in Q4 2022. 237 funds tracked by Wall St. Rank hold EDIT as of Q2 2023.

Edgestream Partners reported no remaining Editas Medicine position as of Q2 2023 after selling out during the quarter.
Edgestream Partners sold 154,789 Editas Medicine shares in Q2 2023, an estimated $1.12M.
Edgestream Partners first reported a position in Editas Medicine in Q3 2022 and held it in 3 quarters.
Edgestream Partners's Editas Medicine position peaked at $2.65M in Q4 2022.
237 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2023.

Based on Edgestream Partners's 13F filing for Q2 2023, filed 10 Aug 2023.